Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
BACK TO LIST

Laboratory Report

Patient
Name: Hayward, Tom
DOB: 07-APR-1975 (Age: 50)
Gender: male
Address:
391 Dean locks
M1 Manchester (United Kingdom)
ID: 3376-612163-7 (ECI)
Report
Date: 14-FEB-2019
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Cornbrook Medical Practice
City Road 204
M3 3 Manchester (United Kingdom)
Specimen
Collected: 14-FEB-2019

Chemistry

Test 14-FEB-2019 Reference Range Unit
Glucose [Mass/volume] in Serum or Plasma 80.0 70 - 100 mg/dL
Urea nitrogen [Mass/volume] in Serum or Plasma 13.3 7 - 20 mg/dL
Creatinine [Mass/volume] in Serum or Plasma 1.9 H 0.6 - 1.2 mg/dL
Calcium [Mass/volume] in Serum or Plasma 9.1 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Serum or Plasma 136.2 135 - 145 mmol/L
Potassium [Moles/volume] in Serum or Plasma 4.5 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Serum or Plasma 103.3 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Serum or Plasma 21.5 L 22 - 32 mmol/L
Ketones [Presence] in Urine by Test strip Urine ketone test = +
Hemoglobin A1c/Hemoglobin.total in Blood 3.3 L 4.0 - 5.6 %
Glucose [Mass/volume] in Blood 80.0 70 - 100 mg/dL
Urea nitrogen [Mass/volume] in Blood 13.3 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 2.0 H 0.6 - 1.2 mg/dL
Calcium [Mass/volume] in Blood 9.1 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 136.2 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.5 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 103.3 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 21.5 L 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 166.3 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 136.0 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 84.2 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 55.0 40 - 60 mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine 22.0 0 - 30 mg/g

Urinalysis

Test 14-FEB-2019 Reference Range Unit
Glucose [Mass/volume] in Urine by Test strip 0.6 0 - 5 mg/dL
Glucose [Presence] in Urine by Test strip Urine glucose test = ++
Bilirubin.total [Mass/volume] in Urine by Test strip 0.2 0 - 1 mg/dL
Bilirubin.total [Presence] in Urine by Test strip Finding of bilirubin in urine
Ketones [Mass/volume] in Urine by Test strip 17.5 0 - 20 mg/dL
Specific gravity of Urine by Test strip 1.0 L 1.005 - 1.030 {nominal}
pH of Urine by Test strip 6.3 5.0 - 8.0 pH
Protein [Mass/volume] in Urine by Test strip 269.9 H 0 - 20 mg/dL
Protein [Presence] in Urine by Test strip Urine protein test = ++
Nitrite [Presence] in Urine by Test strip Urine nitrite negative
Hemoglobin [Presence] in Urine by Test strip Urine blood test = negative
Leukocyte esterase [Presence] in Urine by Test strip Urine leukocyte test negative

Specimen information

Test 14-FEB-2019 Specimen
Appearance of Urine Cloudy urine Urine
Odor of Urine Urine smell ammoniacal Urine
Clarity of Urine Translucent Urine
Color of Urine Brown color Urine

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows elevated creatinine, low total CO₂, and significant proteinuria, suggesting possible renal impairment with metabolic acidosis. Urinalysis reveals protein, glucose, ketones, bilirubin, low specific gravity, and abnormal appearance, supporting renal dysfunction and possible tubular involvement. HbA1c is low despite glucosuria, which may indicate renal glycosuria rather than diabetes. Recommend nephrology evaluation and further assessment for underlying renal pathology.